Cover Image
市場調查報告書

EpiCast Report:腫瘤的支持療法的流行病學的預測

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 595458
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:腫瘤的支持療法的流行病學的預測 EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026
出版日期: 2017年12月01日 內容資訊: 英文 39 Pages
簡介

本報告提供全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的,各種癌症、腫瘤的支持療法的市場趨勢和今後預測相關分析,目前患病人數和發病情形 (各年齡、男女等),今後10年的患病數量的預測值等調查

第1章 目錄

第2章 腫瘤的支持療法:摘要整理

第3章 流行病學

  • 疾病的背景情況
  • 全球各國的過去的趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 腫瘤的支持療法:流行病學的預測 (今後11年份)
    • 各種癌症的發病數量 (確診)
    • 接受了化療的所有癌症的發病數量 (確診)
    • 化療的副作用的發病數量 (確診)
    • 前列腺癌症的發病數量 (確診)
    • 產生了骨轉移的,前列腺癌症的發病數量 (確診)
    • 乳癌的發病數量 (確診)
    • 產生骨轉移的乳癌的發病數量 (確診)
    • 肺癌症的發病數量 (確診)
    • 產生骨轉移的肺癌症的發病數量 (確診)
    • 各種癌症的發病數量預測:今後5年份
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER174-17

Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation in any part of the body that may spread beyond the cells' normal boundaries (WHO, 2017). Worldwide, it is estimated that around 14 million new cases of cancer are diagnosed each year, and 30-50% of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017). The etiology of cancer varies with each type; however, the most common risk factors include tobacco use, lack of physical exercise, unhealthy diet, and old age (WHO, 2017).

In 2016, there were more than 900,000 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with more than 75% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remainder of about 24% casesreceived chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were more than 800,000 cases of chemotherapy-induced anemia and almost 750,000 cases of chemotherapy-induced nausea and vomiting in the 7MM.

In 2016, Spain had the highest age-standardized diagnosed incidence of all cancer in men at more than 570 cases per 100,000. Germany had the lowest age-standardized diagnosed incidence of all cancer in men at around 428 cases per 100,000.The US had an age-standardized diagnosed incidence of all cancer of about 435 cases per 100,000 in 2016. As far as womenare concerned, in 2016, the US had the highest age-standardized rate of over 400 cases per 100,000, while Japan had the lowest rate at around 325cases per 100,000. The UK had the highest age-standardized rate of around 400 cases per 100,000 out of the five European countries (5EU: France, Germany, Italy, Spain, and UK).

The report "EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026", provides an overview of the global and historical trends for all cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all cancer segmented by age (beginning at 18 years and ending at 80 years and older) and sex. It also provides the proportion of all cancer cases treated with chemotherapy and the number of those cases that develop a chemotherapy-induced condition.

Furthermore, this report provides the number of diagnosed incident cases of prostate (men ages 35 years and older), breast (women ages 20 years and older), and lung cancer (men and women ages 20 years and older), and the proportion of those that metastasize to bone. Finally, the report also provides a forecast of the five-year diagnosed prevalent cases of all cancer in men and women combined (ages 18 years and older).

Scope

  • The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
  • The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Supportive Care in Oncology EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
  • Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
  • Understand magnitude of chemotherapy induced conditions.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Supportive Care Oncology: Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Global and Historical Trends 8
  • 3.3 Forecast Methodology 10
    • 3.3.1 Sources 10
    • 3.3.2 Forecast Assumptions and Methods 17
  • 3.4 Epidemiological Forecast for Supportive Care in Oncology (2016-2026) 23
    • 3.4.1 Diagnosed Incident Cases of All Cancer 23
    • 3.4.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment 23
    • 3.4.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions 24
    • 3.4.4 Diagnosed Incident Cases of Prostate Cancer 25
    • 3.4.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis 26
    • 3.4.6 Diagnosed Incident Cases of Breast Cancer 27
    • 3.4.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis 28
    • 3.4.8 Diagnosed Incident Cases of Lung Cancer 29
    • 3.4.9 Diagnosed Incident Cases of Lung Cancer That Develop Bone Metastasis 30
    • 3.4.10 Five-Year Diagnosed Prevalent Cases of All Cancer 31
  • 3.5 Discussion 32
    • 3.5.1 Epidemiological Forecast Insight 32
    • 3.5.2 Limitations of Analysis 33
    • 3.5.3 Strengths of Analysis 33

4 Appendix 34

  • 4.1 Bibliography 34
  • 4.2 About the Authors 37
    • 4.2.1 Epidemiologists 37
    • 4.2.2 Reviewers 37
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 38
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38
  • 4.3 About GlobalData 39
  • 4.4 Contact Us 39
  • 4.5 Disclaimer 39

List of Tables

  • Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages ≥20 Years 23

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years 5
  • Figure 2: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages ≥18 Years, 2016-2026 9
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages ≥18 Years, 2016-2026 10
  • Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer 11
  • Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer 12
  • Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer 13
  • Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer 14
  • Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer 15
  • Figure 10: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions 16
  • Figure 11: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer 17
  • Figure 12: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years 24
  • Figure 13: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years 25
  • Figure 14: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years 26
  • Figure 15: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages ≥35 Years 27
  • Figure 16: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages ≥20 Years 28
  • Figure 17: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages ≥20 Years 29
  • Figure 18: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages ≥20 Years 30
  • Figure 19: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages ≥20 Years 31
  • Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages 32
Back to Top